Edgewise is sponsoring an Industry Forum, "Spotlight on Becker muscular dystrophy: Understanding the lived experience of Becker and clinical advancements with a novel agent." Only conference attendees ...

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference – Company to host an Industry Forum to discuss ...

Multiparametric quantitative MRI could potentially help differentiate between Duchenne muscular dystrophy and Becker muscular dystrophy early and improve the management of these conditions.

Details of the Edgewise presentations at MDA: Edgewise Industry Forum Edgewise is sponsoring an Industry Forum, “Spotlight on Becker muscular dystrophy: Understanding the lived experience of ...

Title: P10: Prediction of North Star Ambulatory Assessment trajectories in Becker muscular dystrophy: Model development and validation Title: P11: Two-year sevasemten treatment outcomes in Becker ...

Edgewise Therapeutics' stock soars on positive Becker Muscular Dystrophy trial results. Learn why EWTX is a promising buy with derisked programs.

at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The conference will take place at the Hilton Anatole, Dallas, TX from March 16-19, 2025.

Italfarmaco's rare disease unit includes programs in Duchenne muscular dystrophy, Becker muscular dystrophy, amyotrophic lateral sclerosis, and polycythemia vera. For more information visit ...

ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, today announced the opening of the company's new U.S. headquarters in Concord, Massachusetts. The 10,000-square-foot facility located at 575 ...

Thrivent has once again received the World's Most Ethical Companies® recognition by Ethisphere, a global leader in defining ...